News and Trends 27 Nov 2020
uniQure Stocks Up With First Phase III Results of Hemophilia B Gene Therapy
Gene therapies for the rare blood clotting disorder hemophilia B have taken a step closer to the market as Dutch developer uniQure became the first to release interim phase III results last week. Hemophilia is an inherited disease caused by mutations to genes encoding blood clotting proteins, resulting in uncontrollable bleeds. In severe cases of […]